Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Crescent Biopharma (CBIO) Amortization of Deferred Charges (2020 - 2021)

Crescent Biopharma (CBIO) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $189440.0 as the latest value for Q3 2021.

Quarterly Amortization of Deferred Charges rose 10.08% to $189440.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $731302.0 through Sep 2021, changed N/A year-over-year, with the annual reading at $680845.0 for FY2020, 9.8% up from the prior year.
Amortization of Deferred Charges for Q3 2021 was $189440.0 at Crescent Biopharma, up from $184935.0 in the prior quarter.
The five-year high for Amortization of Deferred Charges was $189440.0 in Q3 2021, with the low at $164262.0 in Q1 2020.